Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Figure FS2 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
  1. Home
  2. Publications
  3. Figure FS2 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Figure FS2 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Authors:
  • PPPeng Peng
    Peng Peng
  • XQXiaoyan Qiang
    Xiaoyan Qiang
  • GLGuoyu Li
    Guoyu Li
  • LLLin Li
    Lin Li
  • SNShumao Ni
    Shumao Ni
  • QYQi Yu
    Qi Yu
  • LSLaura Sourd
    Laura Sourd
  • EMElisabetta Marangoni
    Elisabetta Marangoni
  • CHChao Hu
    Chao Hu
  • DWDong Wang
    Dong Wang
  • DWDi Wu
    Di Wu
  • FWFrank Wu
    Frank Wu

Open Access
Publisher website
Google Scholar
  • 27 November 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1535-7163.30733719
Abstract
As shown in Figure 2, Image J was applied for semi-quantification for each protein level as indicated.
Keywords
  • DRUG TARGETS
  • ONCOGENES & TUMOR SUPPRESSORS
  • SMALL MOLECULE AGENTS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.